Scholars Central

Conference abstractPublished 28 Apr 2016

In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems

Authors: M Mashat

Toxicology & Drug Research Centre, KSA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Chronic infections with Pseudomonas aeruginosa are a leading cause of morbidity in patients with cystic fibrosis (CF). The aim of tobramycin inhalation therapy in CF patients with chronic pulmonary infection is to deliver high amounts of drug directly to the site of infection. TOBIÃ?® is a tobramycin nebulizer solution (300mg/5ml) approved by FDA for maintenance therapy for patient with CF. The 20% tobramycin sulfate solution was reported as the optimal and maximal concentration. Methods: Nebulization of high strength tobramycin solution (20% tobramycin sulfate) (HSTS) has been assessed in this study by using different selected high performance nebulizer delivery systems: two different designs of jet nebulizers, and three new nebulizers based on vibrating mesh technology. The aerosol particle size distribution and output characteristics were measured for in vitro performance assessment of the nebulizer systems. The methodology was adapted from the current European standard, EN 13544- 1:2001E. Results: The particle size distribution characteristic measurements showed that all tested nebulizers may be suitable for inhalation of HSTS. The mean (SD) of highest percentage of fine particles (<5Ã?¼m) was 77.64 (2.3)% for SidestreamÃ?®, at flow rate 16 L/min. The highest respirable inhaled mass was for Pari LC PlusÃ?® combined with PariBoyNÃ?® compressor, with mean (SD) 90.85 (8.6) mg. The mean (SD) of highest drug wastage percentage was 63.9 (3.9) % for SidestreamÃ?® jet nebulizer combined with compressed air cylinder at flow rate 16L/min, while the lowest was 2.3 (0.26)% for NE-U22 OmronÃ?® (high frequency). Conclusions: The HSTS can be nebulized by all tested nebulisers but the high frequency NE-U22 OmronÃ?® and Aeroneb GoÃ?® are more efficient. When the HSTS compared to TOBIÃ?®, the respirable inhaled dose was increased to more than 73%.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Developing Drugs.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “M Mashat”